1-3 of 3
Kevin J. Hamblett
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

SGN-35C: A Novel CD30-Directed Antibody-Drug Conjugate for the Treatment of Lymphomas

Kevin J. Hamblett, Julia Cochran, Katie Snead, Steven Jin, Roma Yumul, Jessica Simmons, Ivan Stone, Ryan Lyski, Jason P. Schrum, Andrea R. Lim, Astrid Clarke
Journal: Blood
Blood (2023) 142 (Supplement 1): 1440.
https://doi.org/10.1182/blood-2023-182400
Published: 2023
Journal Articles

SGN-35, an Anti-CD30 Antibody-Drug Conjugate, Exhibits Potent Antitumor Activity for the Treatment of CD30 + Malignancies.

Kevin J. Hamblett, Jeremy Barton, Charles G. Cerveny, Jamie B. Andreyka, Kim M. Kissler, Nicole M. Okeley, Ivan Stone, May K. Sutherland, Michael M. Sun, Peter D. Senter, Alan F. Wahl, Nathan C. Ihle
Journal: Blood
Blood (2005) 106 (11): 610.
https://doi.org/10.1182/blood.V106.11.610.610
Published: 2005
Journal Articles

The Anti-CD30 Monoclonal Antibody SGN-30 Inhibits Hodgkins Disease Growth and Sensitizes Cells to Established Chemotherapeutics.

Charles G. Cerveny, MS, Che-Leung Law, PhD, Renee S. McCormick, BS, Joel S. Lenox, MS, Kevin J. Hamblett, PhD, Lori E. Westendorf, BS, Andrew K. Yamane, BS, Joseph M. Petroziello, MS, Joseph A. Francisco, PhD, Alan F. Wahl, PhD
Journal: Blood
Blood (2004) 104 (11): 2639.
https://doi.org/10.1182/blood.V104.11.2639.2639
Published: 2004